Navigation Links
PharmAthene Reports First Quarter 2009 Financial and Operational Results
Date:5/15/2009

a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

  • For more information about PharmAthene, please visit www.PharmAthene.com.

    Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product cand
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
    4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
    5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
    6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
    7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
    8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
    9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
    10. PharmAthene to Delay Release of Full Year 2007 Financial Results
    11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report ... the current state of the global Propanol market with a focus on the Chinese ... Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and ...
    (Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
    (Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
    (Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a ... technical service business units, Whitehouse Laboratories is pleased to announce that it has begun ... Container Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, ...
    Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
    ... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.527 04/2002 , , , ... , Microorganism , Propionibacterium ... type , Bacteria, gram positive, , ...
    ... , , , , , , Multiporator , , , ... Transformation Protocol , Protocol No. 4308 915.047 11/2001 , ... , , , , ... , Cell type , Filamentous fungus, protoplasts, ...
    ... , , , , , Multiporator , , , , ... Transformation Protocol , Protocol No. 4308 915.048 11/2001 , ... , , , Organism , ... Cell type , Filamentous fungus, conidia, , ...
    Cached Biology Technology:Propionibacterium freudenreichii 2Neurospora crassa 2Neurospora crassa 2
    (Date:7/8/2015)... , N.J. and NEW YORK , ... and Guidepoint today announced BD & ... healthcare companies with free access to Guidepoint,s expert network ... start-ups that are developing cutting-edge technologies to improve healthcare ... dedicated Guidepoint research manager, each start-up entrepreneur will be ...
    (Date:7/7/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a ... a revised version of one of its first 30 second commercials ... in New York , Chicago ... Francisco metro areas.    , , , ... all the cards in your wallet and keep your identity secure. ...
    (Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
    Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
    ... ASHEVILLE, NC The USDA Forest Service Southern Research Station (SRS) ... on the southern pine beetle, a native bark beetle that ... of the southern United States. Southern pine beetle ... States, causing more than $60 million in damage and lost ...
    ... The Greenland ice sheet can experience extreme melting even ... analysis by Dr. Marco Tedesco, assistant professor in the Department ... New York. His findings suggest that glaciers could undergo ... difficult to halt. "We are finding that even if ...
    ... Understanding the influence of genetics, lifestyle and environment ... of research for University of Louisville School of Public ... Nandita Das and Stephanie Denkhoff. Through a ... program established with a grant from Susan G. Komen ...
    Cached Biology News:'Southern Pine Beetle II' 2Extreme melting on Greenland ice sheet, reports CCNY team 2Extreme melting on Greenland ice sheet, reports CCNY team 3UofL students seek answers to breast cancer disparities in minority populations 2UofL students seek answers to breast cancer disparities in minority populations 3
    ... ovens are designed to create the ideal environment ... (ambient to 99.9C) , Variable speed control ... samples, whether it be for washing or hybridizing ... current temperature inside the chamber, ,is situated above ...
    ... magnetic particle based purification systems provide high ... any sample. They offer increased throughput and ... systems- KingFisher, KingFisher mL and KingFisher 96, ... l. Each system consists of an instrument, ...
    ... is the latest edition to the famous ... an extra large diameter exhaust port for ... panel allows precise setting and control of ... handling large quantities and samples , ...
    ... Thermo Savant SpeedVac Concentrators set the standard ... SC110A SpeedVac uses a combination of centrifugal force, ... a single run., SC110A comes equipped with:, , ... chemical compatibility , ...
    Biology Products: